Development of a Process to a 4-Arylated 2-Methylisoquinolin-1(2<i>H</i>)-one for the Treatment of Solid Tumors: Lessons in Ortho-Bromination, Selective Solubility, Pd Deactivation, and Form Control-Reference-Cited by-同舟云学术

Development of a Process to a 4-Arylated 2-Methylisoquinolin-1(2H)-one for the Treatment of Solid Tumors: Lessons in Ortho-Bromination, Selective Solubility, Pd Deactivation, and Form Control

Published:2022-04-20 Issue:5 Volume:26 Page:1458-1469
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Primer David N.¹^ORCID,Yong Kelvin¹,Ramirez Antonio²^ORCID,Kreilein Matthew¹^ORCID,Ferretti Antonio C.¹,Ruda Antonio M.³,Fleary-Roberts Nadia³,Moseley Jonathan D.³⁴^ORCID,Forsyth Siân M.³,Evans Graham R.³,Traverse John F.¹⁵

Affiliation:

1. Chemical Process Development, Bristol Myers Squibb, 556 Morris Ave, Summit, New Jersey 07901, United States

2. Chemical Process Development, Bristol Myers Squibb, 1 Squibb Dr, New Brunswick, New Jersey 08901, United States

3. CatSci Ltd., CBTC2, Capital Business Park, Wentloog, Cardiff CF3 2PX, U.K.

4. Scientific Update Ltd, Maycroft Place, Stone Cross, Mayfield TN20 6EW, U.K.

5. Kymera Therapeutics, 200 Arsenal Yards Blvd, Suite 230, Watertown, Massachusetts 02472, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.2c00057

Reference24 articles.

1. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family

2. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence

3. Achieving clinical success with BET inhibitors as anti-cancer agents

4. Bennett, M. J.; Betancort, J. M.; Boloor, A.; Kaldor, S. W.; Stafford, J. A.; Veal, J. M. Heterocyclic Compounds as Bromodomain Inhibitors and Their Preparation, WO2015/058160 A12015.

5. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suzuki–Miyaura Coupling of Aryl Nosylates with Diethanolamine Boronates;Synthesis;2023-06-07